Latest Breaking News On - National vaccine serum institute - Page 1 : comparemela.com

  The new recombinant COVID-19 vaccine, developed by the National Vaccine &Serum Institute, a R&D center of Sinopharm s bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday.   The vaccine is based on the structural features of the receptor binding domain (RBD) on the virus spike protein (S-protein). It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralizing antibodies.   The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.

Liao yifanProducts institute co ltdChina national biotec groupNational health commissionNational medical products administration onNational vaccine serum instituteWuhan institute of biological productsNational vaccineSerum instituteNational medical products administrationWuhan instituteBiological productsப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட்சீனா தேசிய பயோடெக் குழுதேசிய ஆரோக்கியம் தரகுதேசிய தடுப்பூசி சீரம் நிறுவனம்